169 related articles for article (PubMed ID: 35671604)
1. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis.
Kwon WK; Jang HJ; Lee JE; Park YH; Ryu JM; Yu J; Jang JH; Kim JW
Cancer Genet; 2022 Aug; 266-267():19-27. PubMed ID: 35671604
[TBL] [Abstract][Full Text] [Related]
2. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
Cao WM; Gao Y; Yang HJ; Xie SN; Ding XW; Pan ZW; Ye WW; Wang XJ
BMC Cancer; 2016 Feb; 16():64. PubMed ID: 26852015
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
Meng H; Yao L; Yuan H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(11):3044-3052. PubMed ID: 31957001
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
[TBL] [Abstract][Full Text] [Related]
6. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
[TBL] [Abstract][Full Text] [Related]
8. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients.
Bang YJ; Kwon WK; Nam SJ; Kim SW; Chae BJ; Lee SK; Ryu JM; Kim JW; Yu J; Lee JE
Cancer Res Treat; 2022 Jul; 54(3):827-833. PubMed ID: 34645131
[TBL] [Abstract][Full Text] [Related]
10. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
11. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
13. Double Heterozygosity for Rare Deleterious Variants in the
Madar L; Majoros V; Szűcs Z; Nagy O; Babicz T; Butz H; Patócs A; Balogh I; Koczok K
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895014
[TBL] [Abstract][Full Text] [Related]
14. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
15. Five Italian Families with Two Mutations in
Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Dello Ioio C; Cioffi M; Molinari AM
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33287145
[TBL] [Abstract][Full Text] [Related]
16. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
[TBL] [Abstract][Full Text] [Related]
17. A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.
Kechin A; Boyarskikh U; Barinov A; Tanas A; Kazakova S; Zhevlova A; Khrapov E; Subbotin S; Mishukova O; Kekeeva T; Demidova I; Filipenko M
Breast Cancer Res Treat; 2023 Jan; 197(2):387-395. PubMed ID: 36367610
[TBL] [Abstract][Full Text] [Related]
18. Clinically Significant Unclassified Variants in
Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
[TBL] [Abstract][Full Text] [Related]
19. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Li H; Engel C; de la Hoya M; Peterlongo P; Yannoukakos D; Livraghi L; Radice P; Thomassen M; Hansen TVO; Gerdes AM; Nielsen HR; Caputo SM; Zambelli A; Borg A; Solano A; Thomas A; Parsons MT; Antoniou AC; Leslie G; Yang X; Chenevix-Trench G; Caldes T; Kwong A; Pedersen IS; Lautrup CK; John EM; Terry MB; Hopper JL; Southey MC; Andrulis IL; Tischkowitz M; Janavicius R; Boonen SE; Kroeldrup L; Varesco L; Hamann U; Vega A; Palmero EI; Garber J; Montagna M; Van Asperen CJ; Foretova L; Greene MH; Selkirk T; Moller P; Toland AE; Domchek SM; James PA; Thorne H; Eccles DM; Nielsen SM; Manoukian S; Pasini B; Caligo MA; Lazaro C; Kirk J; Wappenschmidt B; Spurdle AB; Couch FJ; Schmutzler R; Goldgar DE; ;
Genet Med; 2022 Jan; 24(1):119-129. PubMed ID: 34906479
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls.
Park JS; Nam EJ; Park HS; Han JW; Lee JY; Kim J; Kim TI; Lee ST
Cancer Res Treat; 2017 Oct; 49(4):1012-1021. PubMed ID: 28111427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
